BackKaryopharm Therapeutics Overview

Karyopharm Therapeutics Selling, General & Admin

Selling, General & Admin expenses for KPTI.

Quarterly SG&A Expenses

$26.68M
↓ 2.44% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$104.54M
↓ 7.69% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin